Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cantharidin - Verrica Pharmaceuticals

Next Previous
Drug Profile

Cantharidin - Verrica Pharmaceuticals

Alternative Names: Cantharidin 0.7% topical solution; TO-208; VP 102 - Verrica Pharmaceuticals; VP 103; VP 103 - Verrica Pharmaceuticals; VP-102; YCANTH

Latest Information Update: 12 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verrica Pharmaceuticals
  • Developer Torii Pharmaceutical; Verrica Pharmaceuticals
  • Class Antivirals; Benzofurans; Epoxy compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Molluscum contagiosum
  • Phase III Warts
  • Phase II Genital warts

Most Recent Events

  • 09 Feb 2026 Launched for Molluscum contagiosum in Japan (Topical)
  • 17 Dec 2025 Phase-III clinical trials in Warts (In children, In adults, In adolescents, In the elderly) in USA (Topical) (NCT07246590)
  • 15 Nov 2025 Verrica Pharmaceuticals plans a phase III trial for Warts in USA(Topical) in 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top